Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17744968 | 0.91 | RXFP1 (0.75) | KMT2AMEN1RXFP1MAPK1TP53 | |
| SCHEMBL5462777 | 0.88 | RXFP1 (0.78) | KMT2AMEN1RXFP1MAPK1TP53 | |
| SCHEMBL12260301 | 0.87 | RXFP1 (0.71) | KMT2AMEN1RXFP1MAPK1TP53 | |
| SCHEMBL12260302 | 0.87 | RXFP1 (0.71) | KMT2AMEN1RXFP1MAPK1TP53 | |
| SCHEMBL12260543 | 0.86 | RXFP1 (0.69) | KMT2AMEN1RXFP1MAPK1TP53 | |
| SCHEMBL12260506 | 0.86 | RXFP1 (0.69) | KMT2AMEN1RXFP1MAPK1TP53 | |
| SCHEMBL12260311 | 0.86 | RXFP1 (0.69) | KMT2AMEN1RXFP1MAPK1TP53 | |
| SCHEMBL17816993 | 0.86 | RXFP1 (0.69) | KMT2AMEN1RXFP1MAPK1TP53 | |
| SCHEMBL14747684 | 0.86 | KMT2A (0.74) | KMT2AMEN1RXFP1MAPK1TP53 | |
| SCHEMBL19919963 | 0.85 | RXFP1 (0.68) | KMT2AMEN1RXFP1MAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190231787-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-01 | — | — | US | disclosed |
| WO-2018039641-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | PHARMATROPHIX, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190231787-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | ADH1A, NTRK2, ADH1C | KMT2A 1542/4885MEN1 4538/4885RXFP1 1348/4885 |
| US-20110230479-A1 | NEUROTROPHIN MIMETICS AND USES THEREOF | BDNF, NTRK2, NGF | KMT2A 4245/4885MEN1 3442/4885RXFP1 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.